KNSA — Kiniksa Pharmaceuticals, Ltd.
$76.73-5.03%
Last close: · regular session
Last 60 sessions
KNSA closed at $76.73 (-5.03%) on Oct 23, 2026. Float: 39.2M shares. Latest SEC filing: 8-K on May 29, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for KNSA in the TickerWise workspace.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: BM
- Exchange: NASDAQ
- Employees: 315
- Website: https://www.kiniksa.com
Latest SEC filings for KNSA
Latest KNSA news
- Kiniksa Pharmaceuticals International, plc Q3 2026 Earnings Preview Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.